Acquisition of 50.8B Won in Convertible Bonds from Affiliate… Intended for Financial Restructuring but Poses Significant Credit Risk

APTOCROM decides to acquire 50.8 billion won in 20th series unregistered, unsecured private convertible bonds issued by its affiliate Aprogen Biologics, settled by offsetting existing loan receivables.
The CBs have a 2% coupon rate, 4% yield-to-maturity, a conversion price of 3,778 won per share, and a conversion period from June 4, 2027 to May 4, 2029.
Bondholders have a put option to demand early redemption every 3 months starting from December 4, 2027 (1.5 years after issuance).
The issuer, Aprogen Biologics, has recorded significant net losses for three consecutive years (2023: -113.3B won, 2024: -105.0B won, 2025: -168.3B won), indicating weak financial health.
The acquisition amount of 50.8B won far exceeds APTOCROM's market cap of approximately 33.8B won and represents 18.52% of its equity of 274.3B won.
This related-party transaction aims to improve the financial structure by converting loans into CBs, but the issuer's distress poses substantial credit risk.
[AI Comprehensive Analysis]This CB acquisition replaces book loans with convertible bonds, having no direct cash flow impact, but the exposure to a struggling affiliate is excessive compared to market cap, leading to high credit risk. Without a turnaround in the issuer's performance, recovery of principal and interest is uncertain, potentially deteriorating asset quality over the long term.